Alnylam Pharma (ALNY) Tops Q4 EPS by 19c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $251.65 --0%
EPS Growth %: -39.0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -39.0%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($2.09), $0.19 better than the analyst estimate of ($2.28). Revenue for the quarter came in at $21.03 million versus the consensus estimate of $15.12 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Truist Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
